Drugs / T lymphocytes iCASP9 ΔCD19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02849886 | Apr 2019 → Dec 2021 | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Centre Hospitalier Universitaire de Besancon | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T lymphocytes iCASP9 ΔCD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02849886 ↗ |
| Modality | Cell therapy | “genetically modified T-lymphocytes administered” NCT02849886 ↗ |
| Route | Intravenous | “Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene” NCT02849886 ↗ |